Considering that compensatory signals mediated by insulin receptor-A or IGF-IR/IR hybrids may contribute to the lack of efficacy of anti-IGF agents [229], simultaneous inhibition of the IGF system and HIF-1α might prevent compensatory signaling, therefore providing an alternative strategy for the therapeutic management of diverse tumors including breast cancer. The gene discussed is HIF1A; the disease is breast carcinoma.